Cargando…

Gliotoxicity of the cyanotoxin, β-methyl-amino-(L)-alanine (BMAA)

The amino acid variant β-methyl-amino-(L)-alanine (BMAA) has long been associated with the increased incidence and progression of the amyotrophic lateral sclerosis/Parkinsonism dementia complex (ALS/PDC). Previous studies have indicated that BMAA damages neurons via excitotoxic mechanisms. We have c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Alexander S., Gehringer, Michelle M., Braidy, Nady, Guillemin, Gilles J., Welch, Jeffrey H., Neilan, Brett A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601369/
https://www.ncbi.nlm.nih.gov/pubmed/23508043
http://dx.doi.org/10.1038/srep01482
Descripción
Sumario:The amino acid variant β-methyl-amino-(L)-alanine (BMAA) has long been associated with the increased incidence and progression of the amyotrophic lateral sclerosis/Parkinsonism dementia complex (ALS/PDC). Previous studies have indicated that BMAA damages neurons via excitotoxic mechanisms. We have challenged rat olfactory ensheathing cells (OECs) with exogenous BMAA and found it to be cytotoxic. BMAA also induces a significant increase in Ca(2+) influx, enhanced production of reactive oxygen species (ROS), and disrupts mitochondrial activity in OECs. This is the first study investigating BMAA toxicity using pure glial cells. These findings align BMAA with the three proposed mechanisms of degeneration in ALS, those being non-cell autonomous death, excitotoxicity and mitochondrial dysfunction.